CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

346

Enrollment

OTHER

Sponsor class

Conditions

Shock, Cardiogenic

Interventions

DRUG: Dobutamine
DRUG: Milrinone
DRUG: Normal Saline

Sponsor

Ottawa Heart Institute Research Corporation